1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6550449F50B0DDB97852581230063B963
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-what-it-takes-to-successfully-launch-an-oncology-product-in-the-usa-marketplace-staffing-benchmarks?opendocument
18
19opendocument
203.81.28.94
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Resource Allocation

What it Takes to Successfully Launch an Oncology Product in the U.S. Marketplace: Staffing Benchmarks

ID: 5460


Features:

8 Info Graphics

17 Data Graphics

250+ Metrics


Pages/Slides: 33


Published: 2017


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "What it Takes to Successfully Launch an Oncology Product in the U.S. Marketplace: Staffing Benchmarks"


STUDY OVERVIEW



Some U.S. Oncology product launches become blockbusters, while others stumble to achieve only a small portion of their expected potential. How can pharmaceutical companies ensure an organization is providing the needed FTEs before, during and after a product's launch?

This benchmarking study is designed to provide staffing benchmarks across pre-launch, launch and post-launch activities for new oncology products launched in the U.S. This analysis probes Oncology product staffing levels for 12 companies and 20 U.S. project launches. The study will help marketing and brand leaders identify staffing priorities across pre-launch, launch and post-launch activities.

NOTE: Survey responses have two segmentations - Total Benchmark Class and Product’s Projected Peak Annual Revenue.

KEY TOPICS

  • Key Trends and Market Patterns
  • Total Staffing Benchmarks Segmented by Peak Year Sales Forecast
  • Staffing Benchmark Analysis for Launch Activities
  • Total Benchmark Class: Launch Staffing by Year

SAMPLE KEY METRICS

  • Total Staffing for each Product Launch Year, Year -3, -2,-1, Launch Year, Year+1
  • Peak Year Sales Forecast Segments: Total Staffing for each Product Launch Year, Year -3, -2,-1, Launch Year, Year+1
  • Estimate of FTEs Allocated to Each of the 11 Activities for each Product Launch Year, Year -3, -2,-1, Launch Year, Year+1
  • Peak Year Sales Forecast Segments: Estimate of FTEs Allocated to Each of the 11 Activities for each Product Launch Year, Year -3, -2,-1, Launch Year, Year+1
  • In Launch Year -3, How Many Staff Members were Allocated to the Following 3 Activities
  • In Launch Year -2, How Many Staff Members were Allocated to the Following 7 Activities

SAMPLE KEY FINDING

  • Year -1
    FTEs spike dramatically during Year -1 in preparation for Launch Year. Market research staffing levels reflect high activity from Year -1 to Year +1. Increased competition in established markets also increases FTEs needed.
  • Launch Year
    Sales, medical affairs, and managed markets staff all jump up in Launch Year. One year post-launch, sales and managed markets staffing levels peak. Brand-specific marketing FTEs increase steadily, peaking during the Launch Year.

METHODOLOGY


This analysis probes Oncology product staffing levels for 12 companies and 20 U.S. project launches. Executives at the VP level, Functional Heads, Senior Directors and Directors were among the participants who informed this study. The analysis examines staffing allocations at each launch stage as well as across critical Medical and Commercial activities for various market-entry situations.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Health Care; Manufacturing; Consumer Products; Diagnostic; Medical Device


Companies Profiled:
EMD Serono; Tesaro; Amgen; Pfizer; OTSUKA; Nektar Therapeutics; Medivation; Astellas; Novartis; Bayer; Lilly; Regeneron

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.